- Previous Close
700.65 - Open
697.05 - Bid --
- Ask --
- Day's Range
655.45 - 697.05 - 52 Week Range
288.90 - 835.20 - Volume
374,527 - Avg. Volume
539,429 - Market Cap (intraday)
53.312B - Beta (5Y Monthly) 0.30
- PE Ratio (TTM)
33.90 - EPS (TTM)
19.54 - Earnings Date --
- Forward Dividend & Yield 0.80 (0.12%)
- Ex-Dividend Date Sep 20, 2024
- 1y Target Est
644.00
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, anti-malarial products, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, it also offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, the company is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessasion, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic, stem cell transplantation, and anti-migraine. The company was founded in 1987 and is headquartered in Mumbai, India.
www.supriyalifescience.comRecent News: SUPRIYA.NS
View MorePerformance Overview: SUPRIYA.NS
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SUPRIYA.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SUPRIYA.NS
View MoreValuation Measures
Market Cap
53.25B
Enterprise Value
52.43B
Trailing P/E
33.90
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.72
Price/Book (mrq)
5.89
Enterprise Value/Revenue
8.57
Enterprise Value/EBITDA
22.23
Financial Highlights
Profitability and Income Statement
Profit Margin
25.20%
Return on Assets (ttm)
34.42%
Return on Equity (ttm)
18.99%
Revenue (ttm)
6.25B
Net Income Avi to Common (ttm)
1.58B
Diluted EPS (ttm)
19.54
Balance Sheet and Cash Flow
Total Cash (mrq)
843.14M
Total Debt/Equity (mrq)
0.61%
Levered Free Cash Flow (ttm)
-468.51M